Celigo assists in optimizing CHO cells for biopharmaceutical production

The Novo Nordisk Center for Biosustainability (Denmark) set out to improve the efficiency of Chinese hamster ovary (CHO)-cell based production of non-monoclonal antibody, therapeutic glycoproteins designed to serve as biopharmaceuticals. To optimize the growth and production capacities of these CHO cells, the scientists looked at: lipid-based transfection, cell cultivation, cell counting, and antibody-independent product titer. Different growth and transfection parameters were investigated to see which yielded the highest growth profiles and production capacities. The Celigo was used in combination with Hoechst and propidium iodide to count the cells in 96-well format. The system developed here miniaturized the process and allowed [...]

Nexcelom’s Celigo Detects CRISPR Transfection Efficiency of sgRNA in CHO Cells

Introduction Chinese hamster ovary (CHO) cells are the cell type of choice for biopharmaceuticals due to their propensity to correctly fold and post-translationally modify human proteins [1]. Here, researchers use an optimized bioinformatics tool (“CRISPy”) to generate chimeric RNA called “single guide” RNA (sgRNA) in order to disrupt FUT8, a gene that is utilized in N-glycosylation. This novel web-based tool ensures efficient, fast, and low-cost genetic manipulation of CHO cells for future biopharmaceutical applications. Materials and Methods Cell culture and transfection of CHO cells CHO cells were cultured and transfected by Nucleofector Kit V with 1 μg of Cas9 plasmid [...]

By | 2015-03-30T09:00:16+00:00 March 30th, 2015|Categories: Celigo User Publications|Tags: , , , , |0 Comments